In The News - Neurology
Clinical Lab Products | June 08, 2020
Quanterix, Billerica, Mass, is expanding its menu of ready-to-use Simoa kits to include tau phosphorylated at threonine 181 (p-tau 181), a highly specific biomarker for the study of Alzheimer’s disease pathology in cerebrospinal fluid, plasma, and serum.
June 28, 2019
News of the Quanterix acquisition of UmanDiagnostics, which aired on NPR'S Morning Edition, Friday June 28.
Bloomberg | May 21, 2019
By Kanoko Matsuyama May 21, 2019, 4:00 PM EDT
Chemical and Engineering News | March 13, 2019
by Jyoti Madhusoodanan, special to C&EN JANUARY 14, 2019 | APPEARED IN VOLUME 97, ISSUE 2
Boston Business Journal | February 19, 2019
by Allison DeAngelis – Life Sciences Reporter, Boston Business Journal Feb 19, 2019, 6:04am EST Could a blood test diagnose Alzheimer's disease up to 16 years before a person begins showing symptoms? The chief executive at Lexington-based Quanterix Corp. believes so.